# mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

> clinical trial · VERIFIED · 2026-06-15

Status: ACTIVE_NOT_RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: BRCA1 Mutation Carrier

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT02208375

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.